Literature DB >> 11743648

Induction of differentiation and suppression of malignant phenotype of human neuroblastoma BE(2)-C cells by valproic acid: enhancement by combination with interferon-alpha.

Jindrich Cinatl1, Rouslan Kotchetkov, Roman Blaheta, Pablo Hernáiz Driever, Jens Uwe Vogel, Jaroslav Cinatl.   

Abstract

Valproic acid (VPA) has been shown to induce growth-arrest and differentiation of human neuroectodermal tumors similarly to several other fatty acids. In the present study, we show that continuous VPA treatment together with Interferon-alpha (INF-alpha) synergistically inhibited cell growth of a well-established model of neuroblastoma (NB) differentiation using the human N-myc amplified cell line BE(2)-C. Suppression of tumor growth was accompanied by morphological features of neuronal differentiation and inhibition of histone deacetylase activity. Furthermore, induction of differentiation was concomitant with altered expression of genes related to malignant phenotype such as down-regulation of N-myc, induction of bcl-2 and neural cell adhesion molecule. Production of inhibitors of angiogenesis like thrombospondin-1 and activin A was up-regulated in differentiated NB cells. Treatment with VPA alone decreased the ability of BE(2)-C cells to adhere to and penetrate human endothelium. All these effects of VPA were significantly enhanced when combined with INF-alpha which on its own had little or no effect. These results suggest that combination of VPA and INF-alpha may provide a novel therapeutic strategy for NB due to enhanced inhibition of tumor cell growth, induction of tumor differentiation and suppression of malignant biology by reduced angiogenic and decreased metastatic potentials.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11743648

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  19 in total

Review 1.  Epigenetic therapy of leukemia: An update.

Authors:  Nitin Jain; Adriana Rossi; Guillermo Garcia-Manero
Journal:  Int J Biochem Cell Biol       Date:  2008-10-17       Impact factor: 5.085

Review 2.  Chromatin, cancer and drug therapies.

Authors:  Connie C Cortez; Peter A Jones
Journal:  Mutat Res       Date:  2008-07-22       Impact factor: 2.433

Review 3.  Hijacking HES1: how tumors co-opt the anti-differentiation strategies of quiescent cells.

Authors:  Liyun Sang; James M Roberts; Hilary A Coller
Journal:  Trends Mol Med       Date:  2009-12-18       Impact factor: 11.951

4.  The G1 phase arrest and apoptosis by intrinsic pathway induced by valproic acid inhibit proliferation of BGC-823 gastric carcinoma cells.

Authors:  Xia Zhao; Weihua Yang; Changwen Shi; Wanshan Ma; Jianing Liu; Yunshan Wang; Guosheng Jiang
Journal:  Tumour Biol       Date:  2010-11-27

5.  Chromatin remodelling at the topoisomerase II-beta promoter is associated with enhanced sensitivity to etoposide in human neuroblastoma cell lines.

Authors:  Chandra M Das; Peter E Zage; Pete Taylor; Dolly Aguilera; Johannes E A Wolff; Dean Lee; Vidya Gopalakrishnan
Journal:  Eur J Cancer       Date:  2010-10       Impact factor: 9.162

6.  Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation.

Authors:  Cynthia K Hahn; Kenneth N Ross; Ian M Warrington; Ralph Mazitschek; Cindy M Kanegai; Renee D Wright; Andrew L Kung; Todd R Golub; Kimberly Stegmaier
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-07       Impact factor: 11.205

7.  The histone deacetylase inhibitor valproic acid sensitizes diffuse large B-cell lymphoma cell lines to CHOP-induced cell death.

Authors:  Malin Ageberg; Karin Rydström; Thomas Relander; Kristina Drott
Journal:  Am J Transl Res       Date:  2013-03-28       Impact factor: 4.060

8.  Targeting angiogenesis for controlling neuroblastoma.

Authors:  Subhasree Roy Choudhury; Surajit Karmakar; Naren L Banik; Swapan K Ray
Journal:  J Oncol       Date:  2011-08-25       Impact factor: 4.375

9.  Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells.

Authors:  Chung Heon Ryu; Wan Soo Yoon; Kwang Ywel Park; Seong Muk Kim; Jung Yeon Lim; Ji Sun Woo; Chang Hyun Jeong; Yun Hou; Sin-Soo Jeun
Journal:  J Biomed Biotechnol       Date:  2012-06-04

10.  Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study.

Authors:  Alma Chavez-Blanco; Blanca Segura-Pacheco; Enrique Perez-Cardenas; Lucia Taja-Chayeb; Lucely Cetina; Myrna Candelaria; David Cantu; Aurora Gonzalez-Fierro; Patricia Garcia-Lopez; Pilar Zambrano; Carlos Perez-Plasencia; Gustavo Cabrera; Catalina Trejo-Becerril; Enrique Angeles; Alfonso Duenas-Gonzalez
Journal:  Mol Cancer       Date:  2005-07-07       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.